Antoxerene Overview

  • Founded
  • 2016
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Antoxerene General Information

Description

Developer of drug discovery platform created to develop small molecule drugs that target protein-drug and protein-protein interactions in pathways related to aging. The company is focused on small molecule discovery through the study of protein-protein interactions and identifying and developing novel compounds to selectively destroy the toxic senescent cells and restore tissue function, thus enabling healthcare organizations to help the patients to reap the benefits of pathways of aging.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2521 Route 20
  • La Fayette, NY 13084
  • United States
+1 (518) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Antoxerene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 00.00 Completed Out of Business
1. Seed Round 25-Aug-2017 00.00 00.00 00.00 Completed Pre-Clinical Trials
To view Antoxerene’s complete valuation and funding history, request access »

Antoxerene Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Antoxerene’s complete cap table history, request access »

Antoxerene Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 12-Jul-2018 00000 0000000 0000 Drug Discovery 000000 00000 00.0
To view Antoxerene’s complete investments history, request access »